One Health Company, a Palo Alto, Calif.-based bio company making precision medicine accessible for dogs, raised $10M in financing.
The round was led by Polaris Partners and Borealis Ventures, with participation from existing investors Andreessen Horowitz, Lerer Hippeau, Y-Combinator, and Tau Ventures.
The company intends to use the funds to accelerate the expansion of its flagship product, FidoCure®.
Led by Christina Lopes, co-founder and CEO, One Health provides FidoCure®, which allows pet parents and veterinarians to access a human-grade precision medicine platform for dogs. Currently available in all US states at more than 200 participating veterinarians, FidoCure® already grew its’ patient presence to over 1,000 dogs enrolled.
How Fidocure works:
- Genetic Testing: Fidocure uses next generation sequencing at a Clia certified lab (human grade) to understand the exact genetic mutation that may be driving a dog’s cancer.
- Precision Medicine Report: Clear recommendations to help understand what is driving a dog’s cancer and the therapeutic implications of these mutations.
- Treatment: Genetic sequencing results are used to enable access to individualized, targeted treatment leveraging the latest science available in human and canine oncology.